Outcomes of surgical aortic valve replacement using Carpentier-Edwards PERIMOUNT bioprosthesis series in elderly patients with severe aortic valve stenosis: a retrospective cohort study

Nishioka, Naritomo; Yamada, Akira; Ujihira, Kosuke; Iba, Yutaka; Maruyama, Ryushi; Hatta, Eiichiro; Kurimoto, Yoshihiko; Nakanishi, Koji

doi:10.1007/s11748-016-0698-0

Cited by 9 publications

(10 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other previous investigations have included in the same analysis different valves of the Perimount series. 24 In our population, nine SVD events (1.1%) were observed, occurring at an average 4.5 AE 2.0 years after implantation (5-year Kaplan-Meier survival free from SVD ¼ 99.1% AE 0.5). Three of these cases required reintervention (one redo AVR and two valve-in-valve procedures), while six cases with stable and moderate dysfunction with limited clinical impact were medically managed.…”

Section: Discussionmentioning

confidence: 70%

See 1 more Smart Citation

Hemodynamic Results and Mid-term Follow-up of 850 19 to 23 mm Perimount Magna Ease Valves

Anselmi

Ruggieri

Soulami

et al. 2018

Thorac cardiovasc Surg

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 70%

“…Accordingly, previous articles have included small prostheses only. 24,25 Our article also lacks full hemodynamic data with confirmation of PPM at midterm follow-up.…”

Section: Discussionmentioning

confidence: 90%

Hemodynamic Results and Mid-term Follow-up of 850 19 to 23 mm Perimount Magna Ease Valves

Anselmi

Ruggieri

Soulami

et al. 2018

Thorac cardiovasc Surg

View full text Add to dashboard Cite

show abstract

“…6 The Manga Ease has demonstrated a hemodynamic performance comparable to its predecessor at early timepoints. 7,8 The Trifecta is a newer valve, introduced in our center in 2011. The Trifecta is also implanted in the supraannular position to generate maximal leaflet opening and hemodynamics similar to a stentless valve.…”

Section: Introductionmentioning

confidence: 99%

Six‐year follow‐up of aortic valve reoperation rates: Carpentier‐Edwards Perimount versus St. Jude Medical Trifecta

et al. 2020

View full text Add to dashboard Cite

Background: The Carpentier-Edwards Perimount valves have a proven track record in aortic valve replacement: good durability, hemodynamic performance, rates of survival, and low rates of valve-related complications and prosthesis-patient mismatch. The St. Jude Medical Trifecta is a newer valve that has shown comparable early and midterm outcomes. Studies show reoperation rates of Trifecta are comparable with Perimount valves, with a few recent studies bringing into focus early structural valve deterioration (SVD), and increased midterm SVD in younger patients. Given that midterm data for Trifecta is still sparse, we wanted to confirm the early low reoperation rates of Trifecta persist over time compared with Perimount. Methods: The Maritime Heart Centre Database was searched for AVR between 2011 and 2016, inclusive. The primary endpoint of the study was all-cause reoperation rate. Results: In total, 711 Perimount and 453 Trifecta implantations were included. The reoperation hazards were determined for age: 0.96 (0.92-0.99; p = .02), female (vs. male): 0.35 (0.08-1.53; p = .16), smoker (vs. nonsmoker): 2.44 (0.85-7.02; p = .1), and Trifecta (vs. Perimount): 2.68 (0.97-7.39; p = .06). Kaplan-Meier survival analysis in subgroups-age <60, age ≥60, male, female, smoker, and nonsmokershowed Perimount having lower reoperation rates than Trifecta in patients younger than 60 (p = .02) and current smokers (p < .01). Conclusions: The rates of reoperation of Perimount and Trifecta were comparable, with Trifecta showing higher rates in patients younger than 60 years, and current smokers. Continued diligence and further independent reporting of midterm reoperation and SVD rates of the Trifecta, including detailed echocardiographic follow-up, are needed to confirm these findings.

show abstract

“…A recent study showed that the CEPMs were similarly useful in older Japanese patients with severe aortic stenosis. 11 There are few reports, 12 however, that have evaluated the efficacy of the CEPMs in small-sized patient populations. The aim of this study was to evaluate how to reduce the incidence of PPM by using CEPMs as aortic valve bioprostheses.…”

mentioning

confidence: 99%

Reducing Prosthesis-Patient Mismatch With Edwards Magna Prosthesis for Aortic Valve Replacement

Kume

Fujita

Fukushima

et al. 2017

Circ J

View full text Add to dashboard Cite

Background: Prosthesis-patient mismatch (PPM) is associated with increased mid-term and long-term mortality rates after aortic valve replacement (AVR). This study aimed to evaluate the efficacy of the Carpentier-Edwards Perimount Magna and Magna Ease (CEPMs) aortic bioprostheses to reduce the incidence of PPM. Methods and Results:Altogether, 282 consecutive patients (113 women, mean age 69.9±9.9 years) underwent AVR with a CEPMs between 2008 and 2015. They were divided into 3 groups based on the risk of PPM as a result of their body surface area and aortic annular diameter (BSA/AnnD ratio): low-risk (LR) group: 0.64±0.05 m 2 /cm (n=94); medium-risk (MR) group: 0.73±0.02 m 2 /cm (n=94); high-risk (HR) group: 0.83±0.05 m 2 /cm (n=94). The 30-day mortality rate was 0.4%. The 5-year actuarial survival rates were 93.2%, 92.3%, and 94.8% for groups LR, MR, and HR, respectively. No explants as a result of structural valve deterioration occurred. No patients showed severe PPM, defined as a measured effective orifice area index (EOAI) <0.65 cm 2 /m 2 . Although there were significant (P<0.05) differences in EOAI (0.98±0.2, 0.90±0.21, and 0.88±0.1 cm 2 /m 2 among the LR, MR, and HR groups, respectively), the corresponding transvalvular mean pressure gradients (13.0±5.5, 12.3±4.0, 12.7±5.3 mmHg) and regression rates of the left ventricular mass (29.8%, 28.7%, 28.9%) were similar among groups. Conclusions:CEPMs provide low surgical risk and reduce the risks of PPM, even in HR patients, with excellent hemodynamics.

show abstract

Outcomes of surgical aortic valve replacement using Carpentier-Edwards PERIMOUNT bioprosthesis series in elderly patients with severe aortic valve stenosis: a retrospective cohort study

Cited by 9 publications

References 24 publications

Hemodynamic Results and Mid-term Follow-up of 850 19 to 23 mm Perimount Magna Ease Valves

Hemodynamic Results and Mid-term Follow-up of 850 19 to 23 mm Perimount Magna Ease Valves

Six‐year follow‐up of aortic valve reoperation rates: Carpentier‐Edwards Perimount versus St. Jude Medical Trifecta

Reducing Prosthesis-Patient Mismatch With Edwards Magna Prosthesis for Aortic Valve Replacement

Contact Info

Product

Resources

About